Baidu
map

Envir Heal Persp:基因突变或抵御机体发生砷中毒

2013-05-06 T.Shen 生物谷

数百万年来,进化不仅仅可以控制人类的发育,而且其对于现代人也影响巨大。这是一项在安第斯山脉一个阿根廷小山村进行的一项研究,在这里水中含有高浓度的砷。研究者对村民进行了长期的跟踪研究,发现其机体基因的突变可以使得机体产生足够的、低毒的砷代谢过程,这项研究由隆德大学等处的研究者共同进行,相关研究成果刊登到了国际杂志Environmental Health Perspectives上。 研究者Kari

数百万年来,进化不仅仅可以控制人类的发育,而且其对于现代人也影响巨大。这是一项在安第斯山脉一个阿根廷小山村进行的一项研究,在这里水中含有高浓度的砷。研究者对村民进行了长期的跟踪研究,发现其机体基因的突变可以使得机体产生足够的、低毒的砷代谢过程,这项研究由隆德大学等处的研究者共同进行,相关研究成果刊登到了国际杂志Environmental Health Perspectives上。

研究者Karin表示,我们知道许多细菌和植物都有增强对砷耐受的基因,此前并没有研究揭示此地区的人们是否存在抵御砷中毒的某些保护性基因。饮用水中高水平的砷和一系列的健康问题直接相关。其可以增加癌症风险、心脏病风险及糖尿病风险,对人的健康危害极大。

这项研究中,研究者研究者对该地区人们的基因进行了深入研究,将其机体基因与不同地区的本土人、来自秘鲁的混血儿以及哥伦比亚、墨西哥的本土人基因进行了比较分析。结果表明,三分之二的阿根廷村民携带有基因突变,其可以帮助村民加速对砷的代谢,而秘鲁村民仅仅有二分之一有,其它本土居民仅仅有14%的比例有这种代谢机制。

以前关于人类对环境毒性进化适应的研究非常少,然而,这项研究揭示了控制机体对毒物代谢的某些基因,而且不在不同的人群中存在不同的适应性,依赖于毒物在当地暴露的情况而定。研究者最后希望继续研究,绘制出相应的基因图谱,来提出增加人们对于毒性物质耐受性的相关策略。

基因突变相关的拓展阅读:

Possible Positive Selection for an Arsenic-Protective Haplotype in Humans

Background: Arsenic in drinking water causes severe health effects. Indigenous people in the South American Andes have likely lived with arsenic-contaminated drinking water for thousands of years. Inhabitants of San Antonio de los Cobres (SAC) in the Argentinean highlands generally carry an AS3MT (the major arsenic-metabolizing gene) haplotype associated with reduced health risks due to rapid arsenic excretion and lower urinary fraction of the monomethylated metabolite. Objectives: We hypothesized an adaptation to high-arsenic living conditions via a possible positive selection for protective AS3MT variants and compared AS3MT haplotype frequencies among different indigenous groups. Methods: Indigenous groups were 1) inhabitants of SAC and villages close to Salta in Northern Argentina (N=346), 2) three Native American populations from the Human Genome Diversity Project (HGDP N=25), and 3) five Peruvian populations (N=97). The last two groups have presumably lower historical exposure to arsenic. Results: We found a significantly higher frequency of the protective AS3MT haplotype in SAC (68.7%) compared to HGDP (14.3%, P-value<0.001, Fisher exact test) and Peruvians (50.5%, P-value<0.001). Genome-wide microsatellite (N=671) analysis showed no detectable level of population structure between SAC and Peruvians (measure of population differentiation FST = 0.006) and low levels of structure between SAC and HGDP populations (FST < 0.055 for all pairs of populations compared). Conclusions: Since population stratification seems unlikely to explain the differences in AS3MT haplotype frequencies, our data raises the possibility that, during a few thousand years, natural selection for tolerance to the environmental stressor arsenic may have increased the frequency of protective variants of AS3MT. Further studies are needed to investigate this hypothesis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005275, encodeId=ef9220052e5b3, content=<a href='/topic/show?id=b2bde3496ac' target=_blank style='color:#2F92EE;'>#砷中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73496, encryptionId=b2bde3496ac, topicName=砷中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Oct 20 16:43:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878056, encodeId=5d5f18e805633, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Jun 17 09:43:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725501, encodeId=df4b1e25501ca, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 06 17:43:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318978, encodeId=59a813189e8d6, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595952, encodeId=8f2e15959528d, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-10-20 anan
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005275, encodeId=ef9220052e5b3, content=<a href='/topic/show?id=b2bde3496ac' target=_blank style='color:#2F92EE;'>#砷中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73496, encryptionId=b2bde3496ac, topicName=砷中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Oct 20 16:43:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878056, encodeId=5d5f18e805633, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Jun 17 09:43:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725501, encodeId=df4b1e25501ca, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 06 17:43:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318978, encodeId=59a813189e8d6, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595952, encodeId=8f2e15959528d, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-06-17 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005275, encodeId=ef9220052e5b3, content=<a href='/topic/show?id=b2bde3496ac' target=_blank style='color:#2F92EE;'>#砷中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73496, encryptionId=b2bde3496ac, topicName=砷中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Oct 20 16:43:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878056, encodeId=5d5f18e805633, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Jun 17 09:43:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725501, encodeId=df4b1e25501ca, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 06 17:43:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318978, encodeId=59a813189e8d6, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595952, encodeId=8f2e15959528d, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2014-01-06 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005275, encodeId=ef9220052e5b3, content=<a href='/topic/show?id=b2bde3496ac' target=_blank style='color:#2F92EE;'>#砷中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73496, encryptionId=b2bde3496ac, topicName=砷中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Oct 20 16:43:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878056, encodeId=5d5f18e805633, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Jun 17 09:43:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725501, encodeId=df4b1e25501ca, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 06 17:43:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318978, encodeId=59a813189e8d6, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595952, encodeId=8f2e15959528d, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 mashirong
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005275, encodeId=ef9220052e5b3, content=<a href='/topic/show?id=b2bde3496ac' target=_blank style='color:#2F92EE;'>#砷中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73496, encryptionId=b2bde3496ac, topicName=砷中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Oct 20 16:43:00 CST 2013, time=2013-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878056, encodeId=5d5f18e805633, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Jun 17 09:43:00 CST 2013, time=2013-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725501, encodeId=df4b1e25501ca, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jan 06 17:43:00 CST 2014, time=2014-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318978, encodeId=59a813189e8d6, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595952, encodeId=8f2e15959528d, content=<a href='/topic/show?id=07bfe3495f1' target=_blank style='color:#2F92EE;'>#砷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73495, encryptionId=07bfe3495f1, topicName=砷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=863418313756, createdName=lishizhe, createdTime=Wed May 08 14:43:00 CST 2013, time=2013-05-08, status=1, ipAttribution=)]
    2013-05-08 lishizhe

相关资讯

触发胰腺癌需要一个以上的致癌基因

    来自梅奥诊所的研究人员在新研究中证实触发胰腺癌需要一个以上的致癌基因,第二个因子创造了“完美风暴”使得肿瘤得以形成。这一发表在9月10日《癌细胞》(Cancer Cell)杂志上的论文颠覆了当前所认为的KRAS癌基因突变就足以触发胰腺癌和无限制的细胞生长的观点。     研究结果揭示了关于胰腺癌形成机制和只有少数患者受益于当前治

Nat Med:SARS病毒的“完美疫苗”

       快速突变被认为是病毒适应环境改变的关键,但北卡罗来纳州大学和Vanderbilt大学的研究人员发现,加速突变反而影响了SARS病毒对动物的致病能力。该文章近日发表在《自然—医学》(Nature Medicine)杂志上,为科学家们制造更安全的活病毒疫苗开辟了新途径。          研究人

Mol Cell Biol:鉴别淋巴瘤突变的好坏

  熟悉X战警的人都知道,突变既可以是非常好也可以是非常糟糕,或者介于两者之间。相同的现象确实也发生在肿瘤细胞,肿瘤细胞可能存在的数以百计基因突变使它与人体其它细胞区别开来;科学的挑战是找出哪些突变是有害的以及哪些是无害的。现在,约翰霍普金斯医学院的研究者已经找到了一个将它们区别开来的新方法:他们制备一个与淋巴瘤相关的随机突变基因,检测该突变基因产生的蛋白是如何工作的,并且为肿瘤发生的潜在因子制作

BMJ:接触射线可增加乳腺癌风险(GENE-RAD-RISK研究)

  近期,GENE-RAD-RISK研究表明,接触诊断性放射可增加BRCA1/2基因变异携带者罹患乳腺癌的风险。该研究是由荷兰癌症研究所发起的横跨欧洲三国(法国、英国、荷兰)的大型回顾性队列研究。旨在估计乳腺癌的风险与BRCA1/2基因突变携带者接受诊断性辐射的相关性。文章发表在BMJ上。   2006年至2009年间,研究人员共录入了1993例女性BRCA1/2基因突变携带者。试验主要通过权重

PLoS ONE:筛选FMR1基因突变更易检测卵巢癌和乳腺癌风险

研究人员开展一项基因突变研究,这些突变提高妇女患上乳腺癌和卵巢癌的几率。他们的研究发现可能有助于开发出更便宜和更容易的方法来筛选乳腺癌和卵巢癌。此外,这些令人吃惊的研究发现可能也解释着携带这些乳腺癌突变的人胚胎如何能够存活下来。相关研究于近期刊登在PLoS ONE期刊上。 已知妇女的乳腺癌和卵巢癌易感基因BRCA1和BRCA2(BRCA1/2)能够被用来预测她们患上这两种癌症的风险。当基因BRC

Am J Pathol:诱发肾上腺癌的基因突变

近日,来自密歇根大学综合癌症研究中心和巴西圣保罗大学的研究者通过研究发现,两个不同的遗传突变可以合作从而诱导肾上腺癌发生。这项研究为我们理解这种罕见的致死性的肾上腺癌提供了线索,而且研究者希望为开发特定的疗法提供帮助。 在美国每年大约有600人诊断出肾上腺癌(adrenal cancer),而且其往往是在癌症后期才能够被诊断出来,这样医生几乎没有足够时间治疗这种癌症,常常导致患者死亡。 研究者

Baidu
map
Baidu
map
Baidu
map